Stock Events

Stock Events

Astria Therapeutics

€4.74

0

+€0+0% Monday 20:00

Statistics

Day High

4.74

Day Low

4.74

52W High

4.74

52W Low

4.74

Volume

108

Avg. Volume

0

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2090.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, competing in the biotech space with Astria Therapeutics' focus on rare diseases.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the development of therapies for serious medical conditions, potentially overlapping with Astria's target markets.

Biogen focuses on neurodegenerative diseases and rare disease markets, directly competing with Astria Therapeutics' interest areas.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals specializes in RNAi therapeutics for rare genetic diseases, aligning closely with Astria's focus.

Sarepta Therapeutics

Sarepta Therapeutics is known for its work on genetic modulation therapies, including treatments for rare diseases, making it a direct competitor.

Biomarin Pharmaceutical

BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, competing in the same niche as Astria.

CRISPR Therapeutics

CRISPR Therapeutics is engaged in gene editing, a cutting-edge area that could overlap with Astria Therapeutics' focus on innovative treatments for rare diseases.

Novartis AG, through its advanced gene therapy and innovative healthcare solutions, competes across a broad range of therapeutic areas including rare diseases.

Pfizer operates in various therapeutic areas, including rare diseases, through its internal development and strategic acquisitions, making it a competitor.

Gilead Sciences

Gilead Sciences, with its focus on antiviral drugs and other therapeutic areas, has the potential to compete in the rare disease market space targeted by Astria.

About

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Show more...

CEO

Ms. Jill C. Milne Ph.D.

Employees

78

Country

United States

ISIN

US04635X1028

Listings

0 Comments

Share your thoughts

FAQ

What is Astria Therapeutics stock price today?▼

The current price of 2090.MU is €4.74 EUR — it has increased by +0% in the past 24 hours. Watch Astria Therapeutics stock price performance more closely on the chart.

What is Astria Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Astria Therapeutics stocks are traded under the ticker 2090.MU.

Is Astria Therapeutics stock price growing?▼

2090.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Astria Therapeutics has showed a +0% increase.

How many employees does Astria Therapeutics have?▼

As of May 06, 2026, the company has 78 employees.

In which sector is Astria Therapeutics located?▼

Astria Therapeutics operates in the Health & Wellness sector.

When did Astria Therapeutics complete a stock split?▼

Astria Therapeutics has not had any recent stock splits.

Where is Astria Therapeutics headquartered?▼

Astria Therapeutics is headquartered in Boston, United States.